KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:GUD - CA4990531069 - Common Stock
6 CAD
+0.03 (+0.5%)
Taking everything into account, GUD scores 4 out of 10 in our fundamental rating. GUD was compared to 30 industry peers in the Pharmaceuticals industry. The financial health of GUD is average, but there are quite some concerns on its profitability. GUD shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year GUD has reported negative net income.
GUD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
Of the past 5 years GUD 4 years had a positive operating cash flow.
1.2 Ratios
GUD has a better Return On Assets (-0.33%) than 66.67% of its industry peers.
With a decent Return On Equity value of -0.46%, GUD is doing good in the industry, outperforming 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GUD's Profit Margin has declined in the last couple of years.
GUD's Gross Margin of 42.49% is in line compared to the rest of the industry. GUD outperforms 53.33% of its industry peers.
In the last couple of years the Gross Margin of GUD has declined.
The Profit Margin and Operating Margin are not available for GUD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GUD has less shares outstanding
GUD has less shares outstanding than it did 5 years ago.
GUD has a better debt/assets ratio than last year.
2.2 Solvency
GUD has an Altman-Z score of 2.10. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
With an excellent Altman-Z score value of 2.10, GUD belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
GUD has a debt to FCF ratio of 37.42. This is a negative value and a sign of low solvency as GUD would need 37.42 years to pay back of all of its debts.
GUD's Debt to FCF ratio of 37.42 is in line compared to the rest of the industry. GUD outperforms 60.00% of its industry peers.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
GUD has a Debt to Equity ratio of 0.11. This is in the better half of the industry: GUD outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Altman-Z | 2.1 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
GUD has a Current Ratio of 2.62. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
GUD has a Current ratio of 2.62. This is in the better half of the industry: GUD outperforms 66.67% of its industry peers.
GUD has a Quick Ratio of 1.68. This is a normal value and indicates that GUD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.68, GUD is in the better half of the industry, outperforming 76.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
GUD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.10%, which is quite impressive.
Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
GUD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.70%.
The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
3.2 Future
GUD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 55.65% yearly.
The Revenue is expected to grow by 10.50% on average over the next years. This is quite good.
EPS Next Y-423.2%
EPS Next 2Y-7.89%
EPS Next 3Y41.41%
EPS Next 5Y55.65%
Revenue Next Year20.19%
Revenue Next 2Y14%
Revenue Next 3Y9.74%
Revenue Next 5Y10.5%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
GUD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 141.44, GUD can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GUD is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of GUD to the average of the S&P500 Index (23.40), we can say GUD is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 141.44 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GUD is on the same level as its industry peers.
GUD's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 209.84 | ||
| EV/EBITDA | 12.46 |
4.3 Compensation for Growth
A more expensive valuation may be justified as GUD's earnings are expected to grow with 41.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.89%
EPS Next 3Y41.41%
5. Dividend
5.1 Amount
GUD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:GUD (12/29/2025, 7:00:00 PM)
6
+0.03 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.6%
Inst Owner ChangeN/A
Ins Owners1.87%
Ins Owner ChangeN/A
Market Cap595.74M
Revenue(TTM)413.85M
Net Income(TTM)-3.49M
Analysts78.18
Price Target8.03 (33.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-753.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)-692.08%
EPS beat(4)2
Avg EPS beat(4)-169.96%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)2
Avg EPS beat(8)-354.72%
EPS beat(12)5
Avg EPS beat(12)-190.89%
EPS beat(16)7
Avg EPS beat(16)-395.3%
Revenue beat(2)2
Avg Revenue beat(2)11.78%
Min Revenue beat(2)11.06%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)8.38%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)7
Avg Revenue beat(8)5.34%
Revenue beat(12)11
Avg Revenue beat(12)8.81%
Revenue beat(16)14
Avg Revenue beat(16)8.72%
PT rev (1m)0%
PT rev (3m)0.92%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-250%
EPS NY rev (1m)-40.35%
EPS NY rev (3m)-40.35%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)4.38%
Revenue NY rev (1m)4.68%
Revenue NY rev (3m)4.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 141.44 | ||
| P/S | 1.44 | ||
| P/FCF | 209.84 | ||
| P/OCF | 16.76 | ||
| P/B | 0.78 | ||
| P/tB | 2 | ||
| EV/EBITDA | 12.46 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY0.71%
FCF(TTM)0.03
FCFY0.48%
OCF(TTM)0.36
OCFY5.97%
SpS4.17
BVpS7.72
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% | ||
| FCFM | 0.69% |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Debt/EBITDA | 1.93 | ||
| Cap/Depr | 58.99% | ||
| Cap/Sales | 7.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 80.91% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | 2.1 |
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
EPS Next Y-423.2%
EPS Next 2Y-7.89%
EPS Next 3Y41.41%
EPS Next 5Y55.65%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
Revenue Next Year20.19%
Revenue Next 2Y14%
Revenue Next 3Y9.74%
Revenue Next 5Y10.5%
EBIT growth 1Y-395.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year454.5%
EBIT Next 3Y80.13%
EBIT Next 5Y56.34%
FCF growth 1Y-63.88%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y56.3%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA.
Can you provide the valuation status for KNIGHT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 2 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.
Can you provide the expected EPS growth for GUD stock?
The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to decline by -423.2% in the next year.